Reuters logo
BRIEF-Bayer's Navigate Esus study halted early
October 5, 2017 / 8:22 PM / 15 days ago

BRIEF-Bayer's Navigate Esus study halted early

Oct 5 (Reuters) - Bayer AG:

* Bayer’s navigate esus study halted early as it indicated comparable efficacy between treatment arms

* Says decision to halt trial was taken jointly by academic leadership of trial and sponsor bayer

* Bayer-Study at interim indicates no efficacy improvement over low dose aspirin, very little chance of showing overall benefit if study were completed

* Positive benefit risk profile of rivaroxaban remains unchanged in all licensed indications

* Bayer - while bleeding rates were low overall, an increase in bleeding was observed in rivaroxaban arm compared to low dose aspirin arm Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below